Crinetics Pharmaceuticals, INC Form 4 insider transactions

Richard Scott Struthers, President & CEO of Crinetics Pharmaceuticals, reports the disposal of shares to cover tax obligations related to vesting Restricted Stock Units.

Chief Commercial Officer James Hassard reports acquisition of restricted stock units and stock options in Crinetics Pharmaceuticals.

CFO of Crinetics Pharmaceuticals, Marc Wilson, reports the acquisition of 25,500 restricted stock units and 95,500 stock options.

Richard Scott Struthers, CEO of Crinetics Pharmaceuticals, reports acquisition of shares and stock options, signaling potential confidence in the company's future.

Dana Pizzuti, Chief Medical and Development Officer of Crinetics Pharmaceuticals, acquired shares and options in the company on March 4, 2024.

Jeff E. Knight, Chief Operating Officer of Crinetics Pharmaceuticals, reports acquisition of shares and stock options.

Stephen F. Betz, Chief Scientific Officer of Crinetics Pharmaceuticals, reports the acquisition of 23,000 shares of common stock and options to purchase 87,000 shares.